Search hospitals > California > Burlingame
Mills-Peninsula Medical Center
Claim this profileBurlingame, California 94010
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
193 reported clinical trials
9 medical researchers
Summary
Mills-Peninsula Medical Center is a medical facility located in Burlingame, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Mills-Peninsula Medical Center is involved with conducting 193 clinical trials across 365 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Deepti Behl, and Kristie A. Bobolis.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Ari Baron, MDAlta Bates Summit Medical Center-Herrick Campus7 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
27 reported clinical trials
62 drugs studied
Christopher JonesSutter Medical Center Sacramento3 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
22 reported clinical trials
61 drugs studied
Deepti BehlCalifornia Pacific Medical Center-Pacific Campus4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
49 drugs studied
Kristie A. BobolisAlta Bates Summit Medical Center-Herrick Campus1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
27 drugs studied
Clinical Trials running at Mills-Peninsula Medical Center
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Pancreatic Cancer
Brain Tumor
Meningioma
Stroke
Cancer
ALK Gene Rearrangement
Squamous Cell Carcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This study is evaluating whether a drug called crizotinib may help treat patients with non-small cell lung cancer.
Recruiting2 awards Phase 328 criteria
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to standard treatment (image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab) versus standard treatment alone in treating patients with non-small cell lung cancer that cannot be treated by surgery (inoperable). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. IGRT is a type of radiation that uses a computer to create picture of the tumor, to help guide the radiation beam during therapy, making it more accurate and causing less damage to healthy tissue. Standard chemotherapy used in this trial consists of combinations of the following drugs: cisplatin, carboplatin, paclitaxel, pemetrexed, and etoposide. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It works by stopping the growth and spread of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a certain substance in the body that may help tumor cells multiply. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding SBRT to the standard treatment of IGRT with chemotherapy and immunotherapy may be more effective at treating patients with inoperable non-small cell lung cancer than giving the standard treatment alone.
Recruiting2 awards Phase 314 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This study is evaluating whether the addition of a drug to chemotherapy may help treat non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Mills-Peninsula Medical Center?
Mills-Peninsula Medical Center is a medical facility located in Burlingame, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Mills-Peninsula Medical Center is involved with conducting 193 clinical trials across 365 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Deepti Behl, and Kristie A. Bobolis.